Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ESH CML 2022 | Novel treatment strategies for patients with CML who are intolerant or resistant to available TKIs

Valentin Garcia Gutiérrez • 21 Oct 2022

ESH CML 2022

Chronic Myeloid Leukemia Leukemia Asciminib Venetoclax Vodobatinib

Valentin Garcia Gutiérrez, MD, PhD, Hospital Universitario Ramón y Cajal, Madrid, Spain, discusses the necessity to develop novel treatment strategies for patients with chronic myeloid leukemia (CML) who are resistant or intolerant to available tyrosine kinase inhibitors (TKIs), commenting on asciminib and novel TKIs currently under investigation, as well as the possibility to combine TKIs with other agents. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding, speaking engagements, ad boards: Novartis, BMS, Incyte, Pfizer

The importance of understanding TKI-specific side effects to select the best option for each patient

Valentin Garcia Gutiérrez • 21 Oct 2022

Unmet needs in CML: life-threatening toxicities, QoL & dealing with intolerance and resistance

Valentin Garcia Gutiérrez • 21 Oct 2022

Related Videos

Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens

Christina Peters • 15 Apr 2024

Promising novel agents in AML: menin inhibitors

Mark Levis • 16 Apr 2024

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation

Valentin Ortiz-Maldonado • 16 Apr 2024

Do all patients require maintenance therapy following alloSCT?

Mark Levis • 16 Apr 2024